Tablet lubricants play a key role in pharmaceutical manufacturing, affecting everything from compression behavior to tablet performance and regulatory compliance. If you’ve ever faced challenges with API compatibility, over-blending, or mitigating nitrosamine risks, it may be time to explore safer, more robust alternatives.

This in-depth whitepaper discusses common challenges in tablet lubrication and introduces Compritol® 888 ATO (glyceryl dibehenate)—a proven, nitrosamine-free lubricant that simplifies formulation development and improves batch-to-batch consistency from R&D through commercial scale-up.

What You'll Learn:

• Key differences between common families of lubricants
• Common pitfalls in tablet lubrication—including API degradation, poor dissolution, and blending sensitivity
• How Compritol® 888 ATO (glyceryl dibehenate) delivers low ejection forces, consistent tablet properties, and regulatory peace-of-mind
• Case study: a comparative study evaluating Compritol® vs. alternative tablet lubricants

Whether you're developing a new oral solid dosage form or reformulating to meet evolving regulatory standards, this resource offers practical guidance grounded in real data.

Ready to troubleshoot your tablet formulation challenges?
Fill out the form below to expand your lubrication knowledge and make more informed excipient decisions.